Pravastatin Sodium Tablets Recalled Due to Manufacturing Practice Deviations
Glenmark Pharmaceuticals is voluntarily recalling Pravastatin Sodium 80mg tablets due to Current Good Manufacturing Practice deviations. The nationwide recall affects specific lot numbers and remains ongoing.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II voluntary recall due to CGMP deviations. No illnesses or injuries have been reported in the source material. CGMP deviations represent manufacturing quality and process control concerns rather than identified health hazards, qualifying this as a precautionary voluntary recall typical of Moderate severity.
Plain-English summary
Glenmark Pharmaceuticals Inc., USA, is voluntarily recalling Pravastatin Sodium Tablets, USP, 80mg, in both 90-count and 500-count bottles. The recall is due to Current Good Manufacturing Practice (CGMP) deviations identified during manufacturing.
The affected lots are 17221770, 17221774, 17231251, 17231262, 17232112, and 17232133, with expiration dates ranging from August 2025 through September 2026. The product was distributed nationwide throughout the United States.
Consumers taking Pravastatin Sodium from the affected lots should contact their healthcare provider or pharmacist to determine if their medication is part of this recall. Do not discontinue the medication without professional guidance.
This is a firm-initiated voluntary recall that remains ongoing. For more information, consumers should contact their pharmacist or the FDA.
The recalled product
- Product
- PRAVASTATIN SODIUM (PRAVASTATIN SODIUM)
- Brand
- PRAVASTATIN SODIUM
- Manufacturer
- Glenmark Pharmaceuticals Inc., USA
- Category
- Drug — Statin
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (7)
- Lot # 17221770
- exp. date Aug-25 17221774
- exp. date Aug-25 17231251
- exp. date May-26 17231262
- exp. date May-26 17232112
- exp. date Sep-26 17232133
- exp. date Sep-26
UPCs (3)
- 0316714570013
- 0316714559018
- 0316714560014
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 39 recalled by Glenmark Pharmaceuticals Inc., USA under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 39 products in this recall →Related recalls
Same brand · PRAVASTATIN SODIUM
- ModeratePravastatin Sodium Tablets Recalled Due to Manufacturing Deviations
FDA (Drugs) · 2025-04-16
- ModeratePravastatin Sodium 20mg Tablets Recalled for CGMP Deviations
FDA (Drugs) · 2025-04-16
- ModerateGlenmark Pharmaceuticals Recalls Pravastatin Sodium Tablets 80mg
FDA (Drugs) · 2025-04-16
- HighPravastatin Sodium Tablets Recalled for Failed Dissolution Specifications
FDA (Drugs) · 2024-07-24
- HighFDA Recalls Pravastatin Sodium Tablets Due to Manufacturing Deviations
FDA (Drugs) · 2023-03-08
Same manufacturer · Glenmark Pharmaceuticals Inc., USA
See all →- ModerateAzelaic Acid Gel 15% Recalled Over Grainy, Gritty, or Sandy Texture
FDA (Drugs) · 2026-08-05
- ModerateAlyacen 7/7/7 birth control tablets failed total impurities specification
FDA (Drugs) · 2026-06-24
- ModerateOndansetron tablets recalled because blister packs are not fully sealed
FDA (Drugs) · 2026-01-07
- CriticalFrozen chopped methi recalled after testing positive for Salmonella
FDA (Drugs) · 2025-12-17
- ModerateBisoprolol and hydrochlorothiazide tablets recalled over traces of another drug
FDA (Drugs) · 2025-12-10
Same hazard · manufacturing deviation
See all →- ModerateSynjardy XR Tablets Recalled Due to Manufacturing Deviations
FDA (Drugs) · 2026-07-08
- ModerateDuloxetine delayed-release capsules recalled for N-nitroso impurity contamination
FDA (Drugs) · 2026-05-13
- ModerateiVIZIA Dry Eye Lubricant Drops Recalled for Sterility Assurance
FDA (Drugs) · 2026-05-06
- ModerateFentanyl Citrate Injectable Solution Recalled for cGMP Deviations
FDA (Drugs) · 2026-05-06
- ModerateFurosemide tablets recalled for presence of N-nitroso impurity
FDA (Drugs) · 2026-04-29